Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-28

Study Completion Date

2022-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

NCT04330664

Advanced Cancer Metastatic Cancer Malignant Neoplastic Disease

COMPLETED PHASE1

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

NCT05178888

Advanced Solid Tumor

COMPLETED PHASE1

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

NCT03785249

Advanced Cancer Metastatic Cancer Malignant Neoplastic Disease

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

NCT06130254

Advanced Solid Tumor Non-small Cell Lung Cancers

RECRUITING PHASE1

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

NCT04111458

Solid Tumors, KRAS Mutation; SOS1

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will evaluate safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and BI 1701963 is a SOS1 pan-KRAS inhibitor.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancer Metastatic Cancer Malignant Neoplasm of Colon Malignant Neoplasm of Lung Malignant Neoplastic Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose escalation

Dose escalation of MRTX849 and BI 1701963 to determine maximum tolerated dose in combination

Group Type EXPERIMENTAL

MRTX849

Intervention Type DRUG

KRAS G12C inhibitor

BI 1701963

Intervention Type DRUG

SOS1 Inhibitor

Dose expansion

Expansion cohorts in NSCLC and CRC patients to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with BI 1701963

Group Type EXPERIMENTAL

MRTX849

Intervention Type DRUG

KRAS G12C inhibitor

BI 1701963

Intervention Type DRUG

SOS1 Inhibitor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRTX849

KRAS G12C inhibitor

Intervention Type DRUG

BI 1701963

SOS1 Inhibitor

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

KRAS G12C inhibitor adagrasib SOS1 Inhibitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 1b must be either Non-Small Cell Lung Cancer or Colorectal Cancer)
* Unresectable or metastatic disease
* No available treatment with curative intent
* Adequate organ function

Exclusion Criteria

* History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
* Other active cancer
* Cardiac abnormalities

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No